Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blisibimod in Immune Thrombocytopenic Purpura
NCT01609452Phase 3Withdrawn
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- Dec 2015
- Primary completion
- Jun 2016
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 3 trial of blisibimod in immune thrombocytopenic purpura (ITP), sponsored by Anthera Pharmaceuticals, Inc.. Planned start Dec 2015; status: withdrawn.
02
Drugs
blisibimod
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT01609452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01609452.